A B S T R A C T The nature and extent of somatostatininduced inhibition of pancreatic endocrine secretion were studied by administration of a number of stimuli of either glucagon or insulin to overnight fasted baboons with and without an infusion of linear somatostatin. The stimuli for acute-phase insulin release were intravenous pulses of glucose, tolbutamide, isoproterenol, and secretin. When given 15 min after the start of a somatostatin infusion, these agents were essentially unable to stimulate insulin secretion. Chronic insulin secretion was stimulated by infusions of either glucose or glucagon. Within 10 min of the start of a superimposed infusion of somatostatin, insulin levels fell to less than 40% of prestimulus control and remained suppressed for the duration of the somatostatin infusion. Stimulation of glucagon secretion by insulin-induced hypoglycemia was also blocked by somatostatin.
INTRODUCTION
Somatostatin, a 14-amino acid peptide isolated from ovine hypothalami and subsequently synthesized, has been shown to have potent growth hormone releaseinhibiting effects in both in vivo and in vitro systems (1) (2) (3) (4) (5) (6) . A second pituitary action, the inhibition of thyroid-releasing hormone induced thyroid-stimulating hormone release has also been demonstrated (6) (7) (8) . A fall in plasma glucose was noted (9, 10) during infusions of somatostatin into overnight fasted baboons. Investigations into this phenomenon resulted in the determination that somatostatin inhibits basal pancreatic secretion of insulin and glucagon (9, 10) . Similar phenomena have been reported in man (11, 12) . This inhibition extends to arginine-stimulated secretion of insulin and glucagon (10, 12) . The This paper also examines evidence that the somatostatin-induced fall in plasma glucose in the overnight fasted animal is secondary to the direct effect of somatostatin on pancreatic hormone secretion. More specifically, we will suggest that this fall in glucose levels is secondary to the fall in glucagon and that in the overnight fasted baboon, glucagon plays a major role in controlling minute by minute hepatic glucose production. The influence of basal insulin levels on the minute by minute control of hepatic glucose production is also discussed.
METHODS
The in vivo studies were carried out on conscious, adolescent male baboons (Papio cynocephalhs) weighing [11] [12] [13] [14] kg which had been adapted to living in primate chairs. Silastic catheters, permanently implanted in the vena cava through either jugular or femoral veins, were kept patent by a continuous infusion of normal saline and heparin (10 U of heparin/ml) at the rate of 40-50 ml/24 h. At least 7 days postoperative (catheter implantation) recovery time was allowed before initiation of studies. The animals were housed in one-or two-animal isolation booths, permitting control of environmental conditions. Blood was withdrawn from the catheters which extend outside the booths. Further experimental details may be found in previous publications (13, 14) .
All studies were performed after an overnight fast (18 h ). Plasma glucose was measured by the ferricyanide method on the Technicon Autoanalyzer (Technicon Instruments Corp., Tarrytown, N. Y.). Serum insulin was assayed by the double antibody method of Morgan and Lazarow (15) . Glucagon was measured in extracted plasma (10) by a modification of the immunoassay method of Nonaka and FoA (16) as described by Ensinck, Shepard, Dudl, and Williams (17) . ACTH was kindly measured by Dr. John Kendall (Veterans Administration Hospital, Portland, Ore.) by radioimmunoassay (18) . Cortisol was measured by a competitive protein-binding method (19) . Synthetic linear somatostatin was kindly supplied by Dr. Roger Guillemin of the Salk Institute. Pure, natural secretin was purchased from the Karolinska Institute, Stockholm, Sweden. The tolbutamide (Orinase) was obtained from The Upjohn Company (Kalamazoo, Mich.), isoproterenol HCl from Winthrop Laboratories (New York), glucagon from Eli Lilly and Company (Indianapolis, Ind.).
Two general types of in vivo studies were performed: (a) Acute insulin responses were obtained by giving the animal single intravenous injections of glucose, secretin, isoproterenol, and tolbutamide. Glucagon responses were studied during insulin hypoglycemia. For all of these stimuli the injections were delivered as a pulse over 10 s, followed by saline wash sufficient to purge the dead space of the catheter. The five acute studies were variations on the same protocol. Two pulses of the secretagogue were given. One of these pulses was superimposed on a somatostatin infusion. According to the variations, the acute studies can be further subdivided into three groups. The dose of somatostatin used in all the in vivo studies presented in this paper was 0.8 gg/kg-min with no loading dose. This dose was selected because it was found to be the lowest dose that caused maximum suppression of basal insulin and glucagon levels. Table I summarizes our doseresponse data. Subsequent to obtaining these dose-response data, the use of a loading dose was discontinued because additional studies demonstrated that the 0.8 ug/kg min dose suppressed insulin and glucagon secretion equally with or without the loading dose. The in vitro studies were performed in Dr. Mayer Davidson's Laboratory, University of California at Los Angeles. A full description of the methods has recently been published (20) . In brief, female Sprague-Dawley rats weighing 150-180 g were sacrificed after either a 20-h fast or after being fed. A segment of liver was quickly removed, slices were prepared, and then incubated in one of two solutions: (a) regular Krebs-Ringer bicarbonate (KRB) ' buffer with 150 mM Na+ and 5 mM K+ or (b) modified KRB containing 25 mM Na' and 130 mM K+. The latter solution is used to stabilize intracellular glycogen and allow hormonal influences on glycogenolysis to become demonstrable. Glucose production was determined by measuring the change in concentration of glucose by the ferricyanide method (21) in the medium over 2 h of incubation. The effect of somatostatin (10-v M) on basal-and glucagon-(10 yg/ml) stimulated glycogenolysis was assessed with the modified KRB buffer. The effect of somatostatin (101 M) on gluconeogenesis from glycerol (10 mM) and alanine (10 mM) was assessed with the regular KRB buffer. 10 rats, 5 rats/day on 2 separate days, were used to assess each pathway and 'Abbreviation used in this paper: KRB, Krebs-Ringer bicarbonate.
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Samples were obtained before and 30 min after the start of somatostatin infusion at the indicated doses. (Figs. 1-4) were pooled (n = 16). In the nonpaired t test the somatostatin-induced fall of basal glucose was significant (P < 0.01) as was the somatostatininduced fall of basal insulin (P < 0.01). Fig. 1 Tolbutamide alone and during somatostatin infusion (Fig. 4) . Tolbutamide alone results in an acute insulin spike as well as a more sustained secretion. A concomitant lowering of plasma glucose occurred. The release of insulin by tolbutamide was greatly inhibited during the somatostatin infusion. 20 min after ending the somatostatin infusion, the plasma insulin was elevated, probably reflecting the effect of tolbutamide still circulating (assuming a similar half-life for tolbutamide in baboons as in humans).
Glucose infusion alone and with superimposition of a somiatostatin infusion. (Fig. 5) . The infusion of glucose as expected, caused a rise in serum glucose levels. Glucagon was depressed and insulin rose. These trends were abruptly altered by somatostatin. The glucose concentration decreased. Glucagon and insulin concentrations fell dramatically. Upon termination of the somatostatin infusion, glucose and insulin concentrations quickly returned to their elevated levels whereas the glucagon concentration returned to the glucose suppressed presomatostatin level. Upon termination of the glucose infusion, the fall in plasma glucose concentration was accompanied by a fall in insulin and a slight rise in glucagon concentration. Thus, at the end of the somatostatin infusion, the secretion of glucagon and 'I SC 4 _\ p, _-4 -. FIGURE 3 Isoproterenol pulse alone and during somatostatin infusion. Format as for Fig. 1 induced glucose rise is apparent. However, marked inhibition of insulin secretion by somatostatin occurred. Upon termination of the somatostatin infusion, insulin rose to presomatostatin levels, and glucose fell slightly. Upon termination of the glucagon infusion, glucose and insulin concentrations declined appropriately. Insulin hypoglycemia alone and during somatostatin infusion (Fig. 7) . Insulin-induced hypoglycemia resulted in a prompt increase in glucagon secretion with peak values being obtained within 20-30 min. ACTH and cortisol secretory responses were slightly delayed with cortisol concentrations being elevated for over 2 h.
The hypoglycemia obtained during the somatostatin infusion was prolonged. Though there was partial escape during the 2nd h of somatostatin infusion, the glucagon response to hypoglycemia was markedly inhibited. Probably in response to the more exaggerated and prolonged hypoglycemia during somatostatin, ACTH concentrations were markedly elevated for the duration of the experiment. Cortisol secretion was correspondingly greater and more prolonged during somatostatin infusion. Thus, ACTH and cortisol secretion are apparently not inhibited by somatostatin infusion.
In vitro glucose production. The results of the in vitro studies are given in Table II . Somatostatin at 107 AI had no effect on basal glycogenolysis or on glycogenolysis stimulated by glucagon. Furthermore somatostatin was without effect on gluconeogenesis with either glycerol or L-alanine as the substrate.
DISCUSSION
Somatostatin is a potent and so far universally effective inhibitor of both acute and chronic phases of insulin and glucagon secretion. It differs in many respects from other known inhibitors of insulin release. It is a naturally occurring substance in the mammalian organism (2) and of the known inhibitors shares this attribute only with the catecholamines (22) , serotonin (23) , prostaglandins (24) , glucosamine (25) , and possibly the ammonium ion (26) . Among this group somatostatin is the only peptide inhibitor and it is the most potent in vivo.
Among pharmacologic inhibitors of insulin secretion, propranolol, mannoheptulose, and 2-deoxy-glucose are not able to inhibit as many diverse stimuli for insulin release as somatostatin (25, (27) (28) (29) . Diazoxide and diphenylhydantoin are widely effective inhibitors of insulin secretion (25, 30) , but their in vivo effectiveness does not match that of somatostatin (31, 32) .
Until now, glucose has been the most potent and best established inhibitor of glucagon (33) , although secretin (34) and free fatty acids (35) have also been reported to block glucagon secretion. Somatostatin differs from glucose as an inhibitor of glucagon secretion in that: (a) It almost totally blocks basal release of glucagon (10) ; (b) It is able to markedly inhibit glucagon secretion stimulated by arginine and insulin hypoglycemia; (c) Finally, somatostatin appears to be the only known biologically derived substance which simultaneously inhibits both glucagon and insulin release.
At this time one can only speculate on the mechanism of somatostatin's pancreatic effect. As a polypeptide, somatostatin probably acts on the cell membrane. Its specificity, affecting release of many, but not all, hormones (1, 4, 5, 8) , suggests the presence of specific receptor sites on the membrane. The ubiquity of its effect in the beta cell indicates that its action is on a step leading to insulin secretion that is common to all the stimuli tested. The rapidity with which the beta and alpha cells respond to prevailing signals once somatostatin infusion is stopped indicates that the effects seen are not secondary to a deleterious influence on cell metabolism. fall in basal glucose is due to decreased glucose production (10) . The decreased hepatic glucose production does not appear to be secondary to a direct effect of somatostatin on the liver, because in the rat liver slice preparation, somatostatin was without effect on glucagon-stimulated glycogenolysis or gluconeogenesis from glycerol or from alanine and the infusion of somatostatin into isolated fed rat livers is without effect on glucose production (36) .
We have previously suggested that the decreased hepatic glucose production is due to inhibition of glucagon by somatostatin (10) . This hypothesis is supported by the inability of somatostatin to decrease serum glucose levels during a glucagon infusion (Fig.  6 ). In the overnight fasted animal a consistent fall in glucose secondary to a fall in glucagon implies that in the basal state, minute by minute hepatic glucose production is maintained by the basal glucagon concentration. Basal insulin production in the overnight fasted animal is dramatically diminished by somatostatin infusion. The conclusion is derived from results attained in species as diverse as man and the cat and in systems including the isolated perfused rat pancreas (11, 37) and arteriovenous sampling across the dog pancreas (36, 38) . This decrease in insulin production is unable to prevent the somatostatin-induced fall in hepatic glucose production. If, as we postulate, somatostatin's signal to the liver is a decline in portal vein glucagon levels, these data suggest that the effect of lowered glucagon on hepatic glucose production is not effectively counteracted by the fall in insulin. Questions are thus raised as to the relative contributions of basal glucagon and insulin in the short-term regulation of basal hepatic glucose production. Furthermore, at a point 45 min after beginning a 4-mg/kg min glucose infusion (Fig. 5) , a superimposed somatostatin infusion was also associated with a falling plasma glucose. Though statistical significance of this decrease in glucose cannot be demonstrated, the abrupt change in slope (over three time points) of the glucose curve under the influence of somatostatin suggests that this change is real. If so, it appears that even after maintenance of insulin levels higher than basal for 45 min, an abrupt fall in insulin is unable to prevent a decrease in hepatic glucose output. Again, the falling glucose concentrations are associated with a sharp fall in serum glucagon.
At this time, it is unclear whether somatostatin plays a physiological role in regulating the endocrine pancreas. Physiological or even pathophysiological counterparts to the almost complete endocrine pancreatic blockade seen with the 0.8-Ag/kgmin somatostatin infusion are not known; and, thus, it is unlikely that the alpha and beta cells of the pancreas are exposed endogenously to the concentration of somatostatin that this large dose engenders. Partial inhibition of insulin or glucagon secretion may occur under numerous circumstances, however. The characteristics of somatostatin blockade-its speed of onset, the ease with which it is reversed, the lack of toxicity-are characteristics that would serve well a physiologically active substance. Endogenous somatostatin might then exert a modulatory influence upon the stimulated or unstimulated endocrine pancreas (10) . The data presented in this paper are consistent with the possibility that somatostatin might be part of a control system to which the alpha and beta cells respond. What is not clear is whether endogenous somatostatin actually reaches the pancreas.
